<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ruha, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meghan Spyres, MD, FACMT</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Danzl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1053045322"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will review the management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) snakebites. The clinical manifestations, evaluation, and diagnosis of these snakebites; evaluation and management of bites by coral snakes; and snakebites outside the United States are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6595.html" rel="external">"Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6599.html" rel="external">"Evaluation and management of coral snakebites"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6594.html" rel="external">"Snakebites worldwide: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/93182.html" rel="external">"Snakebites worldwide: Management"</a>.)</p><p></p><p class="headingAnchor" id="H377516135"><span class="h1">FIRST AID</span><span class="headingEndMark"> — </span>The appropriate first aid for snakebites is controversial, and management strategies are primarily based on case series and clinical experience [<a href="#rid1">1,2</a>]. Numerous field measures have been advocated, but none have been shown to improve outcome [<a href="#rid3">3</a>].</p><p>We suggest the following approach for North American (NA) Crotalinae snakebite victims prior to definitive hospital care [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Remove the patient from the snake's territory and keep him or her warm, at rest, and calm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remove any rings, watches, or constrictive clothing from the affected extremity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immobilize the injured body part in a functional or extended position at the level of the heart [<a href="#rid1">1,2</a>]. For extremity bites, some experts advise elevation of the extremity to decrease local pain and swelling. Although there is a theoretical concern for increased systemic toxicity during prehospital care with elevation of the bite site, evidence is lacking that systemic toxicity is increased by the elevated position in patients with pit viper bites. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do <strong>not</strong> apply pressure immobilization, tourniquets, or constrictive dressings. Pressure immobilization refers to a procedure in which an elastic bandage is applied to the affected limb with a goal of delaying venom spread through the lymphatics but is not applicable and not advisable for the initial management of Crotalinae bites. Although pressure immobilization is mentioned as a potential first aid therapy for snakebites in the United States by the American Heart Association [<a href="#rid4">4</a>], no clinical studies in human patients have demonstrated benefit. Most snakebite experts do not support pressure immobilization for Crotalinae snakebites because these venoms cause local tissue toxicity, and sequestering the venom in the affected limb may increase local tissue damage [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1">Pressure immobilization may be useful as a first aid procedure for neurotoxic snakebites and is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/93182.html" rel="external">"Snakebites worldwide: Management", section on 'Pressure immobilization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cleanse the wound.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withhold alcohol and drugs that may confound clinical assessment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transport the patient to the nearest medical facility as quickly as possible, preferably using emergency medical services.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attempts to identify the snake should not endanger the patient or rescuer and should never delay transport to a medical facility. A digital photo taken at a safe distance may be useful. Snakes and decapitated snake heads should not be handled directly because the bite reflex may remain intact in recently killed snakes and result in additional envenomation.</p><p></p><p class="bulletIndent1">Misidentification (particularly in an emergency situation) may have potentially serious outcomes, and patients with possible envenomation should be observed closely [<a href="#rid7">7</a>]. It may be difficult to determine whether a snake is venomous or not. Several characteristics have been proposed but are not a substitute for expert consultation  (<a class="graphic graphic_figure graphicRef73865" href="/z/d/graphic/73865.html" rel="external">figure 1</a>) [<a href="#rid8">8</a>]. Venomous rattlesnakes have a triangular-shaped head, elliptical pupils, and hollow, retractable fangs. By contrast, nonvenomous snakes have rounded heads and pupils and lack fangs but may be very effective mimics of venomous snakes in terms of appearance or behavior.</p><p></p><p>Methods such as tourniquets, incision and oral suction, mechanical suction devices, cryotherapy, surgery, and electric shock therapy have no role in snakebite management [<a href="#rid5">5</a>]. Tourniquets can damage nerves, tendons, and blood vessels; and oral suction can lead to infection [<a href="#rid8">8-10</a>]. Furthermore, venom removal by mechanical suction is minimal at best. In a study of attempted mock venom extraction with a mechanical suction device in human volunteers, suction reduced the total body burden by only 2 percent [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3160399189"><span class="h1">ACUTE MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment depends upon the degree of envenomation [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/6595.html" rel="external">"Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation'</a>.) </p><p class="headingAnchor" id="H4174814061"><span class="h2">Initial stabilization</span><span class="headingEndMark"> — </span>Stabilization of patients with Crotalinae snakebites requires rapid assessment and management of the airway, breathing, and circulation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway and breathing</strong> – In addition to emergency antivenom administration, patients with airway compromise require endotracheal intubation and mechanical ventilation. Patients with the following clinical features are at highest risk:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bites to the face or neck</strong> – Crotalinae snakebites to the face or neck may result in rapid local tissue swelling with airway obstruction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myokymia (rippling muscle movement of the face and extremities)</strong> – Myokymia that is extensive, or involves the muscles of respiration, is associated with respiratory failure [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mohave or Southern Pacific rattlesnake bite</strong> – Some populations of these species possess a neurotoxin that may produce weakness and respiratory failure [<a href="#rid13">13,14</a>]. Although the decision to perform endotracheal intubation and institute mechanical ventilation should be made on clinical grounds (including the need for airway protection associated with bulbar palsy), ancillary studies may provide additional objective information to augment serial clinical assessment in some patients as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6599.html" rel="external">"Evaluation and management of coral snakebites", section on 'Neurologic assessment and respiratory support'</a>.)   </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Circulation</strong> – Emergency management of shock and bleeding followed by timely antivenom administration to patients with progressive tissue swelling or systemic toxicity after Crotalinae envenomation are the most common actions needed when stabilizing patients with Crotalinae snakebites. </p><p></p><p class="bulletIndent1">Hypovolemia from hemorrhage secondary to bleeding, fluid shift into the bitten limb, and/or direct venom effects with vasodilation may cause shock with hypotension. These patients warrant treatment with rapid infusion of isotonic fluids (eg, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or balance crystalloid solutions) or blood (depending upon degree of hemorrhage and to maintain the hematocrit at acceptable levels) and, if shock is not quickly reversed with intravenous fluid boluses, vasoactive medications, like patients with septic shock. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2277743745"><span class="h2">Marked local or systemic envenomation</span><span class="headingEndMark"> — </span>Patients with marked or progressive swelling, hematologic, or other systemic findings of envenomation, or who have bites to the face or neck that show signs of envenomation and a potential for airway obstruction warrant Crotalinae antivenom treatment of local effects, supportive care, and antivenom  (<a class="graphic graphic_algorithm graphicRef138360" href="/z/d/graphic/138360.html" rel="external">algorithm 1</a>). (See <a class="local">'Antivenom therapy'</a> below.)</p><p class="headingAnchor" id="H1521052658"><span class="h3">Antivenom therapy</span></p><p class="headingAnchor" id="H3745201506"><span class="h4">Initial treatment</span><span class="headingEndMark"> — </span>Consultation with a medical toxicologist or other physician with expertise and prior experience treating venomous snakebites is strongly encouraged <strong>before</strong> initiating antivenom therapy. Emergency consultation with a medical toxicologist in the United States is available at 1-800-222-1222. Regional poison control centers can also assist with locating and facilitating transport of antivenom to the treating facility. </p><p>For patients with Crotalinae snakebites and progressive swelling or signs of systemic toxicity, we recommend antivenom therapy  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>). Antivenom should be administered as soon as possible once manifestations of envenomation (beyond minor localized swelling) are evident to both treat existing effects and prevent progression of venom effects. There is no specific time limit for administration of antivenom. Crotalidae Polyvalent-immune Fab (ovine), brand name CroFab (FabAV) [<a href="#rid5">5,15-24</a>] and Crotalidae Immune F(ab')<sub>2</sub> (equine), brand name Anavip (Fab2AV) [<a href="#rid25">25,26</a>], are each approved for North American (NA) Crotalinae snakebites and have similar efficacy as described below. (See <a class="local">'Efficacy'</a> below.)</p><p>For patients with Crotalinae snakebite sites that present a significant possibility for airway obstruction from local tissue swelling (eg, bites to the face or neck with signs of envenomation), we recommend antivenom administration even for mild swelling in the absence of other signs of envenomation. Patients with bites in these locations can have rapid onset of critical airway compromise from local swelling alone.</p><p>For patients exhibiting neurotoxicity (muscle fasciculation and/or motor weakness) after an NA rattlesnake bite, experience using FabAV to reverse these effects is inconsistent: both success and failure in reversing neurotoxic effects with FabAV are reported [<a href="#rid27">27,28</a>], although experience is limited [<a href="#rid29">29</a>]. Patients with airway compromise or depressed respirations warrant emergency endotracheal intubation and mechanical ventilation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative contraindications</strong> – For patients receiving FabAV (CroFab), relative contraindications include allergy to papain, papaya, or FabAV during prior administration. </p><p></p><p class="bulletIndent1">Relative contraindications for the use of Fab2AV (Anavip) include patients with known allergies to horse protein or who have had an allergic reaction to prior therapy with Fab2AV antivenom. </p><p></p><p class="bulletIndent1">When relative contraindications are present, antivenom should only be administered when the benefits outweigh the risks [<a href="#rid24">24</a>]. These patients require pretreatment for anaphylaxis and adjustment of the rate of infusion as described separately. (See <a class="local">'Treatment of acute antivenom reactions'</a> below.)</p><p></p><p class="bulletIndent1">Pregnancy is <strong>not</strong> a contraindication to antivenom administration; indirect experience with other antivenoms suggests that potential adverse effects to the fetus following pregnancy are primarily related to venom effects on the mother. Although acute antivenom reactions may occur in the mother, antivenom plus any required anaphylaxis management is likely the best approach to improved fetal outcome [<a href="#rid24">24,26,30</a>]. Case reports have also documented delivery of healthy newborns soon after FabAV antivenom therapy [<a href="#rid31">31-33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The table summarizes dosing, reconstitution, and administration for Crotalidae Immune F(ab')<sub>2</sub> (equine), brand name Anavip (Fab2AV) and Crotalidae Polyvalent-immune Fab (ovine), brand name CroFab (FabAV)  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>) and is based upon the manufacturer's instructions [<a href="#rid24">24,26</a>]. Snakes inject the same quantity of venom into children and adults. Thus, the dosage of antivenom is <strong>not </strong>dependent upon age or weight but does vary with the severity of<strong> </strong>envenomation; specifically, higher doses of antivenom are needed for patients with hypotension or serious active bleeding [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Antivenom therapy with FabAV or Fab2AV can be associated with potentially severe allergic reactions, but the risk appears to be low (&lt;1 percent) [<a href="#rid25">25</a>]. Nevertheless, antivenom should only be administered in a continuously monitored emergency or intensive care unit setting. <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> ([concentration 1 mg/mL] 0.3 to 0.5 mg intramuscularly [IM] for administration in the anterolateral thigh as well as epinephrine [concentration 0.1 mg/mL] for continuous intravenous [IV] infusion), <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> or similar antihistamine, IV corticosteroids, and inhaled <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> should all be immediately available. (See <a class="local">'Treatment of acute antivenom reactions'</a> below.)</p><p></p><p class="headingAnchor" id="H2718388434"><span class="h5">Treatment of acute antivenom reactions</span><span class="headingEndMark"> — </span>Based upon the comparative trial between FabAV and Fab2AV, the rate of acute serum reaction and serum sickness for patients receiving either FabAV or Fab2AV is approximately 2 to 3 percent [<a href="#rid25">25</a>]. Patients who have previously received Crotalinae antivenom (or, for Fab2AV antivenom, other equine antivenoms) may be predisposed to acute allergic reactions.</p><p></p><p>In patients who experience signs of acute hypersensitivity (eg, anaphylactic shock, oropharyngeal swelling, bronchospasm, or urticaria) or nonimmunologic acute reactions (eg, nausea, vomiting, arthralgia, headache), the clinician should immediately stop antivenom infusion. Patients with signs suggestive of anaphylaxis should receive emergency treatment as outlined in the rapid overview for adults  (<a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">table 2</a>) or children  (<a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Immediate management'</a>.)</p><p>Consultation with a medical toxicologist experienced in the management of Crotalinae snakebites is strongly encouraged for these patients. Further management depends upon the nature of the reaction [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute hypersensitivity</strong> – Once anaphylaxis is controlled, a decision regarding restarting the antivenom infusion should be based on a risk-to-benefit analysis. Clinicians may choose to proceed with antivenom administration in patients who manifest serious systemic toxicity despite the presence of allergy. If resumption of antivenom therapy is chosen, then the patient should receive pretreatment to blunt the allergic response (eg, IV <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> 1.25 mg/kg, maximum single dose 100 mg and/or IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 2 mg/kg, maximum single dose 125 mg), and the clinician should ensure preparation and immediate availability of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> (0.3 to 0.5 mg IM to the anterolateral thigh, 1:1000 preparation or continuous IV infusion of 1:10,000 epinephrine 0.1 to 1 microgram per minute, titrated to effect) before administration of any antivenom. Antivenom should be administered at a lower infusion rate (eg, 25 mL/hour or slower).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute reactions without hypersensitivity</strong> – Because acute reactions are often nonimmunologic in nature, the antivenom infusion may be resumed cautiously and completed at a lower infusion rate (eg, 25 mL/hour).</p><p></p><p>If signs or symptoms of anaphylaxis or hypersensitivity reactions occur again, antivenom administration should be discontinued immediately, appropriate therapy instituted, and the need for further antivenom treatment re-evaluated.</p><p class="headingAnchor" id="H2400862901"><span class="h4">Assessment of response and need for redosing</span><span class="headingEndMark"> — </span>The response to antivenom determines whether or not further doses are required  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>). Control of envenomation is indicated by all of the following [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic stability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in other systemic findings such as vomiting, diarrhea, or altered mental status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of progression of tissue swelling adjacent to the bite site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Partial or complete reversal of hematologic toxicity based upon repeated laboratory studies performed one hour after each dose of antivenom. Studies should include a complete blood count, prothrombin time (PT), international normalized ratio (INR), and fibrinogen.</p><p></p><p>Patients who do not achieve control of envenomation after the initial dose of antivenom warrant repeat dosing under the guidance of a medical toxicologist or physician with similar expertise managing Crotalinae snakebites. </p><p class="headingAnchor" id="H2187314169"><span class="h4">Prevention of early recurrent toxicity</span><span class="headingEndMark"> — </span>Crotalidae Polyvalent-immune Fab (ovine), brand name CroFab (FabAV), and Crotalidae Immune F(ab')<sub>2</sub> (equine), brand name Anavip (Fab2AV), the antivenoms available for Crotalinae snakebites in North America, differ in their rates of early recurrence and duration of effect (see <a class="local">'Efficacy'</a> below). Thus, the approach to preventing early recurrent toxicity depends upon the antivenom used:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>FabAV (CroFab)</strong> – To prevent recurrent toxicity marked by subsequent worsening of local (eg, swelling) or hematologic (eg, platelets or fibrinogen) effects after initial improvement, we suggest that patients with Crotalinae envenomation who have undergone FabAV administration receive scheduled doses of antivenom (two vials every six hours for three doses)  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>) [<a href="#rid5">5,19,24</a>]. Alternatively, if medical toxicology oversight and resources allow, the clinician may choose to perform careful clinical assessment of the bite site and measurement of coagulation studies every six hours to determine the need for additional antivenom [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">Provision of scheduled maintenance doses of FabAV after initial control is achieved may limit recurrence of local venom effects and decrease rates of late hemotoxicity [<a href="#rid21">21,26</a>]. Yet even with use of maintenance doses, late hemotoxicity is reported in approximately 30 percent of patients [<a href="#rid22">22,25,36</a>]. Some experts suggest that in settings where close monitoring of local swelling and coagulation parameters can occur, as-needed dosing of FabAV antivenom may be more appropriate than scheduled dosing. For example, in a retrospective observational study of 310 adults that compared hospital length of stay and total vials used between patients treated with an as-needed versus a scheduled maintenance antivenom regimen, the as-needed group received fewer vials overall (8 versus 16 vials) and had a shorter hospital length of stay (27 versus 34 hours) [<a href="#rid35">35</a>]. Follow-up information was available for over 90 percent of patients in this study, and there were no differences in hospital readmissions, retreatment with antivenom, bleeding, or procedures between groups. However, patients were admitted to a toxicology service managed by full-time toxicology faculty practicing at the bedside and covered by 24-hour onsite medical toxicology fellows. The immediate availability of physicians with a high level of snakebite expertise likely optimized timely detection of local recurrence and hastened administration of antivenom when necessary. From a practical standpoint, this degree of monitoring is not available at most hospitals where snakebite victims are managed. In those settings, a delay in recognition of and response to recurrence of local venom effects could result in increased local tissue injury, and scheduled maintenance dosing of FabAV is preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fab2AV (Anavip)</strong> – Once initial control is achieved (local effects are no longer progressing, hematologic and systemic effects are improving), maintenance doses of Fab2AV are not needed. However, patients should be observed for an additional 18 hours for re-emergence of local or hematologic effects. If these occur, additional doses of antivenom are indicated [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H3070296561"><span class="h4">Identification and treatment of late hemotoxicity</span></p><p class="headingAnchor" id="H2094741222"><span class="h5">Risk of late hemotoxicity</span><span class="headingEndMark"> — </span>Among patients with rattlesnake envenomation who receive FabAV, the risk of late hemotoxicity is approximately 30 percent depending upon the geographic region and snake species involved [<a href="#rid22">22,25,36</a>]. Late hemotoxicity describes either recurrent, delayed onset, or persistent thrombocytopenia, prolonged PT and/or decreased fibrinogen.</p><p>Late hemotoxicity appears to be much less common in patients treated with Fab2AV. In a randomized clinical trial of 121 patients receiving antivenom for a Crotalinae snakebite, 8 percent of patients who received Fab2AV experienced late hemotoxicity compared with 30 percent in the FabAV group [<a href="#rid25">25</a>]. Subsequent small observational studies from New Mexico and Arizona have revealed even lower rates of late hemotoxicity with use of Fab2AV (0 to 5 percent) [<a href="#rid29">29,37</a>]. Recurrent and delayed hemotoxicity may become apparent as early as 24 hours after treatment with FabAV but can develop up to 14 days after initial control with antivenom [<a href="#rid25">25</a>]. This risk is increased in patients with abnormal platelets or fibrinogen within the first 12 hours after FabAV administration [<a href="#rid38">38</a>]. Risk may also be increased in patients with normal platelets and fibrinogen but who exhibit an elevated D-dimer or fibrin split products [<a href="#rid39">39</a>]. However, late, new-onset hematologic abnormalities may develop even without these indicators, likely due to early administration of antivenom to treat swelling, and prevention of onset of hemotoxicity with this treatment [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H3093873706"><span class="h5">Monitoring</span><span class="headingEndMark"> — </span>Since late hemotoxicity can develop following use of FabAV or Fab2AV, and risk cannot be predicted, all patients who receive antivenom warrant monitoring (physical assessment and laboratory studies) for late thrombocytopenia or hypofibrinogenemia according to the antivenom received [<a href="#rid19">19</a>] (see <a class="local">'Prevention of early recurrent toxicity'</a> above): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>FabAV (CroFab)</strong> – Obtain a platelet count and fibrinogen level two to three days after and again five to seven days after last administration of FabAV. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fab2AV (Anavip)</strong> – Obtain a platelet count and fibrinogen level five to seven days after last Fab2AV administration. </p><p></p><p>If any abnormal trends are noted, further laboratory monitoring is indicated. Additionally, patients with additional risk factors for bleeding may require early or more frequent assessments. </p><p class="headingAnchor" id="H1206833372"><span class="h5">Treatment</span><span class="headingEndMark"> — </span>For patients in whom late hemotoxicity is identified, further management is determined based on the specific laboratory values, signs of bleeding, or presence of risk factors for serious bleeding [<a href="#rid17">17,41-43</a>].</p><p>Indications for antivenom therapy of late hemotoxicity with antivenom include:</p><p class="bulletIndent1"><span class="glyph">●</span>Any bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;25,000/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Multicomponent coagulation abnormalities (eg, platelets &lt;50,000/mL and fibrinogen &lt;80mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid conditions or behaviors that increase hemorrhagic risk such as pregnancy, use of antiplatelet or anticoagulant medications, injury prone behaviors or activities, or recent venom-induced systemic shock</p><p></p><p>Retreatment should be performed in consultation with a medical toxicologist or other physician with expertise in managing Crotalinae snakebites. An initial bolus dose of two vials of FabAV or four vials of Fab2AV is a reasonable starting point, with additional doses titrated to the neutralization of ongoing venom effects [<a href="#rid38">38</a>]. In some instances, total reversal of hemotoxicity with FabAV is not possible. In patients who have no significant bleeding, the clinician may choose improvement in coagulation parameters towards normal as an acceptable outcome [<a href="#rid21">21</a>]. Based on limited evidence, Fab2AV may be a more effective treatment for late hemotoxicity that occurs following use of FabAV [<a href="#rid44">44</a>]. </p><p>Isolated late hypofibrinogenemia may be observed in healthy, nonpregnant patients without other risk factors for bleeding. These patients should be monitored for resolution of coagulation abnormalities, should not use medications that inhibit platelets, and should not undergo any surgical procedures or engage in activities that risk injury until hemotoxicity is resolved. Complete resolution may take up to three weeks from the time of envenomation [<a href="#rid41">41-43</a>].</p><p class="headingAnchor" id="H891704718"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Crotalidae Polyvalent-immune Fab (ovine), brand name CroFab (FabAV); and Crotalidae Immune F(ab')<sub>2</sub> (equine), brand name Anavip (Fab2AV) are the two antivenoms available for bites by Crotalinae snakes in North America:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>FabAV (CroFab) </strong>– FabAV consists of the purified Fab fragments of sheep immunoglobulin (IgG) raised against the venom of four snakes: <em>Crotalus atrox</em> (western diamondback rattlesnake), <em>Crotalus adamanteus</em> (eastern diamondback rattlesnake), <em>Crotalus scutulatus</em> (Mohave rattlesnake), and <em>Agkistrodon piscivorus</em> (cottonmouth or water moccasin) [<a href="#rid16">16,38,45</a>].<strong> </strong>When infused, these Fab fragments bind venom in the intravascular space and are renally excreted. The larger volume of distribution, compared with IgG and Fab2AV, results in more rapid decline in circulating antivenom levels. </p><p></p><p class="bulletIndent1">Because approximately 50 percent of patients in the first phase of the clinical trial developed recurrence of local venom effects, routine maintenance doses in the first 18 hours are recommended for control of local effects. The half-life of FabAV is approximately 15 hours and shorter than Crotalinae venom substances, which may be detected for more than two weeks post-envenomation. Thus, recurrence or delayed onset of hemotoxicity is possible in the days to weeks following treatment as antivenom levels decline and may necessitate repeated antivenom administration. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fab2AV (Anavip)</strong> – Fab2AV consists of the purified F(ab')<sub>2</sub> fragments of equine IgG raised against the venom of <em>Bothrops asper</em> and <em>Crotalus simus</em> [<a href="#rid25">25,46</a>]. When infused, these F(ab')<sub>2</sub> fragments bind venom in the intravascular space. Because of the smaller volume of distribution compared with FabAV, circulating antivenom concentrations do not decline as rapidly, and routine maintenance doses in the first 18 hours following initial control are not required. Although no studies have specifically looked at the effectiveness of Fab2AV and time to treatment, it had similar effectiveness to FabAV when given in the same timeframe [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Because the molecular weight of Fab2AV is above the threshold for renal clearance, these fragments are not cleared renally and have a longer half-life (133 hours) than FabAV [<a href="#rid26">26</a>]. Thus, recurrent hematologic toxicities occur at a lower rate than with FabAV [<a href="#rid25">25</a>].</p><p></p><p>Based upon small trials and observational studies, the majority of envenomated patients achieve control of toxicity (local swelling and systemic effects) after initial administration of one or two loading doses of either FabAV or Fab2AV, with some patients requiring additional doses [<a href="#rid18">18-21,23,25,29,37,47,48</a>]. There is an approximately 2 to 3 percent risk of adverse immune reactions or type 1 (acute) and type 3 (delayed, "serum sickness") hypersensitivity; these are typically minor [<a href="#rid25">25</a>].</p><p>Fab2AV appears to have similar initial therapeutic benefit compared with FabAV. For example, in a trial of over 110 children and adults with Crotalinae envenomation, Fab2AV was found to have comparable efficacy as FabAV in terms of initial control of hemotoxicity after rattlesnake envenomation. Individuals receiving Fab2AV also did not require maintenance dosing for continued control of local envenomation effects, had a lower incidence of late hemotoxicity (5 to 10 percent for Fab2AV versus 30 percent for FabAV [relative risk reduction 0.20, 95% CI 0.01-0.37]), and had similar rates of type 1 and type 3 hypersensitivity reactions (2 to 3 percent) [<a href="#rid25">25</a>]. In an observational study of 37 patients with rattlesnake envenomation from the New Mexico regional poison control center, both Fab2AV and FabAV achieved initial control of local effects and managed initial hemotoxicity [<a href="#rid37">37</a>]. The lower risk of late hemotoxicity following use of Fab2AV makes it attractive for use in patients with rattlesnake envenomation. Although uncommon, late thrombocytopenia and coagulation abnormalities have been associated with serious bleeding and mortality [<a href="#rid41">41-43</a>]. </p><p>Among patients receiving FabAV, thrombocytopenia and/or neurologic effects on presentation have been associated with difficulty achieving initial control [<a href="#rid18">18</a>]. In addition, FabAV antivenom did not reverse the thrombocytopenia following a reported timber rattlesnake envenomation [<a href="#rid49">49</a>].</p><p>Prior to the availability of antivenoms active against Crotalinae snakebites and the widespread availability of emergency departments and critical care units, snakebite mortality ranged from 5 to 36 percent in the United States [<a href="#rid50">50-52</a>]. After the introduction of Antivenin Crotalidae Polyvalent (ACP; Wyeth) in the 1950s and the development of widespread availability of emergency and critical care medicine starting in the 1960s, deaths from snakebites dropped to less than 1 percent. For example, analysis of 23,676 venomous snake exposures from 2001 to 2005 reported to the American Association of Poison Control Centers database found a fatality rate of 0.06 percent [<a href="#rid53">53</a>]. Similarly, no fatalities occurred in a United States registry study of 442 native pit viper snakebites occurring from 2013 to 2015 [<a href="#rid54">54</a>]. Thus, the availability of antivenom for most native Crotalinae snakebites combined with other trends in emergency and critical care capability has been associated with a marked and sustained decrease in snakebite mortality in the United States.</p><p>Additional observational experience suggests that untreated Crotalinae envenomation is rarely fatal in regions where copperhead bites predominate but can be life- or limb-threatening. For example, an observational study of 81 adult and pediatric patients who were managed without antivenom therapy after snakebite (45 copperhead, 12 water moccasin [cottonmouth], 10 rattlesnake, and 14 unknown) reported no fatalities or long-term morbidity [<a href="#rid55">55</a>]. However, significant acute toxicity did occur, including hemotoxicity (15 patients), skin necrosis (8 patients), respiratory distress requiring endotracheal intubation (3 patients), hypotension (2 patients), and cardiac arrhythmia (2 patients).</p><p class="headingAnchor" id="H203914525"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Antivenom administration is the mainstay for treatment of envenomation by NA Crotalinae snakes.</p><p>In addition, the clinician should provide pain control and monitor for and be ready to manage hypotension, bleeding, rhabdomyolysis, elevated tissue and/or compartment pressures, and, rarely, respiratory failure.</p><p class="headingAnchor" id="H346750011"><span class="h4">Pain control</span><span class="headingEndMark"> — </span>Although evidence is limited, patients with rattlesnake or water moccasin bites whose clinical course suggests that the risk of coagulation abnormalities or thrombocytopenia is low or patients with copperhead bites and minimal hemotoxicity may receive analgesia for mild to moderate pain with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or nonsteroidal antiinflammatory medications (eg, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>) [<a href="#rid56">56,57</a>]. Severe pain after snakebite frequently warrants treatment with opioid medications (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>).</p><p class="headingAnchor" id="H3824215715"><span class="h4">Coagulation abnormalities and thrombocytopenia</span><span class="headingEndMark"> — </span>Coagulation abnormalities associated with Crotalinae envenomation is primarily due to thrombin-like enzymes or fibrinogenases within the venom. Fibrinogen levels decline without a decrease in other clotting factors [<a href="#rid43">43,58,59</a>]. This pathophysiology contrasts with true disseminated intravascular coagulation (DIC), where fibrinolysis is activated by increased levels of endogenous thrombin. Thus, antivenom administration, and <strong>not</strong> coagulation factor replacement, is the primary treatment for Crotalinae-induced hemotoxicity. (See <a class="local">'Antivenom therapy'</a> above.)</p><p>Multiple venom components may affect platelets, and the mechanism by which thrombocytopenia occurs is complex [<a href="#rid59">59</a>]. Transfused platelets and coagulation factors in fresh frozen plasma are inactivated by Crotalinae venom and should be avoided in patients with Crotalinae-induced hemotoxicity unless the patient has significant bleeding that is uncontrolled by high-dose antivenom administration [<a href="#rid60">60</a>]. If blood products are given in response to acute blood loss, they should be given with additional antivenom to prevent rapid depletion of those components. Venom-induced thrombocytopenia and venom-induced coagulation abnormalities in the absence of blood loss are not indications for administration of blood products.</p><p class="headingAnchor" id="H3813891428"><span class="h4">Rhabdomyolysis</span><span class="headingEndMark"> — </span>Rhabdomyolysis (creatine kinase [CK] ≥1,000 IU/L) with potential for renal failure has been described in approximately 5 percent of patients bitten by rattlesnakes or water moccasins (cottonmouths) but is rare after copperhead bites [<a href="#rid54">54</a>]. The classic triad of rhabdomyolysis consists of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma CK. Primary treatment goals consist of fluid repletion and evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia). (See  <a class="medical medical_review" href="/z/d/html/14034.html" rel="external">"Clinical features and diagnosis of heme pigment-induced acute kidney injury", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p class="headingAnchor" id="H172004224"><span class="h4">Elevated tissue pressures</span><span class="headingEndMark"> — </span>Elevated tissue pressures may complicate Crotalinae bites. Any dressing, constriction band, splint, cast, or other restrictive covering should be removed. Venom is usually introduced into the subcutaneous tissues, and most, if not all, edema occurs in this space. Tissue pressures may increase because of the massive amounts of subcutaneous tissue fluid and because the skin has limits to its elasticity. Swelling, pain, and paresthesias may occur in patients after Crotalinae snakebite, but true elevation in compartment pressure is uncommon. Antivenom administration is the primary treatment in this situation; surgical intervention based on clinical findings alone is inappropriate.</p><p>Generally, increased compartment pressures result from this extrinsic pressure and can be reduced with the administration of adequate amounts of antivenom and elevation. Elevation results in the drainage of subcutaneous edema and contributes to the reduction of the source of increased tissue pressure. (See <a class="local">'Minor envenomation'</a> below.)</p><p class="headingAnchor" id="H3990577220"><span class="h4">Compartment syndrome</span><span class="headingEndMark"> — </span>True compartment syndrome with documented elevations of muscle compartment pressure is uncommon after Crotalinae snakebites, and fasciotomy is rarely indicated. For example, among 442 patients with a snakebite from the North American Snakebite Registry, only eight (2 percent) had clinical findings concerning for compartment syndrome and only two (0.5 percent) had elevated intracompartmental pressure documented, although six received fasciotomy [<a href="#rid54">54</a>].</p><p>Bites to muscles in compartments that are very close to the skin (eg, anterior tibial, hand, or foot compartments) have a higher potential for compartment syndrome. For these patients, antivenom and elevation may still reduce compartment pressures by the reduction of extrinsic pressure, but persistent intracompartmental pressures may remain high. The indications for fasciotomy in this context are unclear. An animal model of direct compartmental injection of venom demonstrated improved outcomes with antivenom alone versus antivenom plus immediate fasciotomy [<a href="#rid61">61</a>]. If there is a concern for clinically significant increased tissue or compartment pressures, direct measurement with an appropriate device should be performed to guide additional management with antivenom and elevation [<a href="#rid62">62,63</a>] (see  <a class="medical medical_review" href="/z/d/html/358.html" rel="external">"Acute compartment syndrome of the extremities", section on 'Measurement of compartment pressures'</a>). Further management should be guided by a medical toxicologist and surgeon with extensive experience caring for victims with a snakebite.</p><p>Full recovery has been described with nonsurgical management of acute compartment syndrome in the hand (compartment pressure of 55 mmHg) in a patient with a rattlesnake bite to the thenar eminence [<a href="#rid64">64</a>]. The patient received large amounts of polyvalent Crotalinae antivenom (46 vials total) and 20 g of IV <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a>.</p><p class="headingAnchor" id="H2781439214"><span class="h4">Neurotoxicity</span><span class="headingEndMark"> — </span>Neurotoxicity may rarely occur after bites by selected NA rattlesnakes (eg, Mohave, Southern Pacific, or timber rattlesnakes). Although antivenom is recommended, it may not reliably reverse neurotoxicity. Patients with airway compromise or depressed respirations warrant emergency endotracheal intubation and mechanical ventilation. (See <a class="local">'Initial stabilization'</a> above and <a class="local">'Initial treatment'</a> above.)</p><p class="headingAnchor" id="H1940875055"><span class="h4">Wound management</span><span class="headingEndMark"> — </span>All patients also require wound management as described below. (See <a class="local">'Minor envenomation'</a> below.)</p><p class="headingAnchor" id="H800812502"><span class="h3">Disposition</span><span class="headingEndMark"> — </span>All patients with signs of envenomation require admission for further observation or for treatment with antivenom and supportive care. Hospitalization is also warranted in the United States for exotic, non-United States snakebites, even in the setting of initially normal clinical appearance. (See  <a class="medical medical_review" href="/z/d/html/6594.html" rel="external">"Snakebites worldwide: Clinical manifestations and diagnosis"</a>.)</p><p>At discharge, patients who have received antivenom should also receive the following instructions and be scheduled for recommended follow-up:</p><p class="bulletIndent1"><span class="glyph">●</span>Seek care if they develop symptoms of serum sickness (fever, rash, muscle pain, arthralgia, or arthritis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seek care for immediate assessment of platelets and fibrinogen level if they develop bleeding (such as epistaxis, gingival bleeding, vaginal bleeding, or rectal bleeding) in the two weeks following the bite.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If they had thrombocytopenia or coagulation abnormalities during their care or were victims of a rattlesnake envenomation, they should avoid contact sports, surgery, or dental work for two weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients bitten by a rattlesnake or cottonmouth, measurement of PT, fibrinogen, hemoglobin, and platelets according to antivenom received:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FabAV – Two to three days after and then again five to seven days after the last dose of antivenom </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fab2AV – Five to seven days after the last dose of antivenom </p><p></p><p class="headingAnchor" id="H2425445632"><span class="h2">Minor envenomation</span><span class="headingEndMark"> — </span>Patients with minor envenomation after an NA Crotalinae snakebite have swelling that is localized to the bite site, and do <strong>not</strong> have other signs of envenomation should <strong>not</strong> routinely receive antivenom. Bites to the face or neck are an important exception. (See <a class="local">'Initial treatment'</a> above.) </p><p>Management should focus on pain control, wound care, immobilization and positioning of the bite site with close monitoring for progression of swelling or development of hemotoxicity or other signs of envenomation  (<a class="graphic graphic_algorithm graphicRef138360" href="/z/d/graphic/138360.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain control</strong> – Patients with mild to moderate pain may receive oral analgesia with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Patients with rattlesnake or water moccasin snakebites whose clinical course suggests that the risk of coagulation abnormalities or thrombocytopenia is low and patients with copperhead bites and minimal hemotoxicity may receive nonsteroidal antiinflammatory medications (eg, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>) [<a href="#rid56">56,57</a>]. Severe pain warrants treatment with IV opioid medications (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound management</strong> – Wound management includes cleansing the skin surface around the bite site with an iodine-containing or other antiseptic solution such as <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, removal of any visible foreign bodies, and administration of tetanus prophylaxis according to the recommended immunization schedule  (<a class="graphic graphic_table graphicRef61087" href="/z/d/graphic/61087.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a>.)</p><p></p><p class="bulletIndent1">The leading edge of swelling and tenderness, when apparent, should be marked and reassessed every 15 to 30 minutes. Alternatively, extremity circumference can be measured both distal and proximal to the bite site. A marker is used to outline the location of the tape measure on the skin so the same locations are used consistently [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Bedside superficial debridement of hemorrhagic bullae (should they occur) to permit recognition of underlying necrosis and to help decide further intervention has been proposed [<a href="#rid65">65</a>]. However, we do <strong>not</strong> recommend this approach because there are insufficient data demonstrating benefit or evaluating the risks, such as infection, of unroofing intact bullae.</p><p></p><p class="bulletIndent1">Antibiotic prophylaxis is <strong>not</strong> indicated. Although snakebites may result in the inoculation of bacteria, infection is rare. A retrospective analysis of over 2500 rattlesnake bites reported to a regional poison control center found an infection rate of at most 1 percent based, in most cases, on clinical appearance [<a href="#rid66">66</a>]. These results may overestimate the frequency of infection in snakebites because inflammation from venom effects may track up lymphatic channels and mimic cellulitis. Thus, only patients with established infections or heavily contaminated wounds should receive antibiotics [<a href="#rid2">2</a>]. Empiric treatment should cover <em>Salmonella</em> species and common human organisms (eg, <em>Staphylococcus aureus</em> and group A <em>streptococcus</em>) until wound culture results are available. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6027.html" rel="external">"Skin and soft tissue infections in children &gt;28 days: Evaluation and management"</a> and  <a class="medical medical_review" href="/z/d/html/3126.html" rel="external">"Nontyphoidal <i>Salmonella </i>bacteremia and extraintestinal infection", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immobilization and positioning</strong> – Proper immobilization and positioning for snakebites to the distal extremities consists of placement of a well-padded posterior splint (preformed, plaster, or fiberglass) in a position of extension that is gently secured to the extremity with a gauze or elastic wrap applied to avoid excessive pressure or restriction of circulation. During hospital care, we advise elevation of the extremity to reduce acute swelling. (See <a class="local">'First aid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired limb function</strong> – Because complete recovery is expected with supportive care alone in patients with minor Crotalinae envenomation that does not progress, expert guidelines recommend that antivenom therapy in patients with bites to a limb be reserved for those who have swelling that is extending from the bite site or is progressing, or have hemotoxic, systemic, or neurotoxic venom effects [<a href="#rid5">5,67-71</a>]. Patients with confirmed copperhead bites appear to be at a lower risk for systemic toxicity and progressive swelling but may have impairment of function due to swelling and pain in the involved extremity long enough to cause significant short-term morbidity (eg, inability to work or attend school). In one study, the duration of this impairment was a median of three weeks with a range of three days to four months [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">Some experts have suggested that antivenom may provide short-term benefit to patients with mild copperhead envenomation with acceptable risk, primarily minor adverse effects, and increased cost of care. However, more data are needed to identify which patients are most likely to benefit and to establish if antivenom improves function enough to offset the potential risk of serious adverse effects, such as anaphylaxis, when only local venom effects are present. As an example, in one small trial of 74 patients with copperhead bites, treatment with polyvalent Crotalinae ovine immune Fab (FabAV, CroFab) modestly improved limb function and reduced use of opioid pain medication at two weeks but did not shorten the time to full recovery compared with placebo [<a href="#rid67">67</a>]. Although the benefit regarding local venom effects in rattlesnake envenomations has not been studied, there is no reason to believe that similar benefits would not apply to these cases as well. Patients who received FabAV had more minor adverse events (eg, pruritus, urticaria, nausea, dizziness, or fever) but no severe effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation and monitoring</strong> – Patients with minor Crotalinae envenomation should be observed for 24 hours for progression of tissue swelling, hemotoxicity, and other systemic toxicity. Platelet and fibrinogen studies should be repeated every six to eight hours after the initial set of studies.</p><p></p><p class="bulletIndent1">Patients with progressive swelling or abnormal coagulation testing during the observation period should receive antivenom as described below. They also warrant assessment for rhabdomyolysis. (See <a class="local">'Antivenom therapy'</a> above and <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discharge instructions</strong> – Patients should be instructed to seek medical care for:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased swelling not relieved by elevation </p><p class="bulletIndent2"><span class="glyph">•</span>Signs of coagulation abnormalities and/or thrombocytopenia (eg, easy bruising, petechiae, bleeding from gums or hematochezia)</p><p class="bulletIndent2"><span class="glyph">•</span>Signs of infection (eg, fever or pus drainage) </p><p class="bulletIndent2"><span class="glyph">•</span>Tissue necrosis </p><p class="bulletIndent2"><span class="glyph">•</span>Pain not controlled by oral analgesia</p><p class="bulletIndent2"><span class="glyph">•</span>Any other acutely concerning changes in signs or symptoms </p><p></p><p class="headingAnchor" id="H3422271915"><span class="h2">Potential dry bite</span><span class="headingEndMark"> — </span>Up to 25 percent of patients with Crotalinae bite will not develop clinical envenomation. However, some patients may be asymptomatic at presentation, yet go on to develop swelling and/or hematologic toxicity over time. All patients presenting with report of potentially venomous snakebites should be placed on a cardiac monitor, have initial laboratory studies obtained, and observed for signs of toxicity (eg, progressive swelling, tachycardia, hypotension, or bleeding). </p><p>For patients with a potential dry Crotalinae snakebite who are at high risk should they have late progression of envenomation including patients with bites to the face, neck, or lower extremity; children &lt;10 years old; adults &gt;65 years old; and patients with medical comorbidities or poor social supports, we suggest hospital admission and observation for 24 hours with repeat laboratory studies every 8 hours.</p><p>All other patients warrant observation for 8 to 12 hours  (<a class="graphic graphic_algorithm graphicRef138360" href="/z/d/graphic/138360.html" rel="external">algorithm 1</a>). </p><p>It is likely that no significant envenomation has occurred if all of the following criteria are met: </p><p class="bulletIndent1"><span class="glyph">●</span>The patient appears well during observation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat laboratory tests (ie, platelet count, PT, INR, and fibrinogen) at six hours are normal (when fibrinogen testing is not available, no elevation in fibrin degradation products [ie, D-dimer or fibrin split products])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No progressive tissue swelling and no systemic toxicity develops during the observation period</p><p></p><p class="headingAnchor" id="H2401624659"><span class="h1">SERUM SICKNESS</span><span class="headingEndMark"> — </span>Serum sickness occurs in about 2 to 3 percent of patients receiving either FabAV or Fab2AV. The evaluation and management of serum sickness is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p class="headingAnchor" id="H3993954920"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Most victims of venomous North American snakebites fully recover. Permanent sequelae are uncommon but may include loss of range of motion, weakness, pain, abnormal sensation (paresthesia, hypesthesia, anesthesia), skin discoloration or tissue loss such as amputation of a digit.</p><p>Tissue necrosis occurs frequently and may require operative debridement. For example, in a prospective cohort of rattlesnake envenomation, tissue necrosis was seen in 40 percent of upper extremity envenomations, despite antivenom administration [<a href="#rid65">65</a>]. Signs on presentation associated with increased risk of necrosis included cyanosis and ecchymosis. In addition, patients with social or regular ethanol use were more likely to develop necrosis, and regular cocaine use was associated with an increased risk of surgical debridement.</p><p>Death following Crotalinae snakebite is unusual (&lt;1 percent of all bites) [<a href="#rid53">53,54</a>]. Mortality is most often associated with rattlesnake bites [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H1909802040"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3586935387"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H4026498286"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112692.html" rel="external">"Society guideline links: Envenomation by snakes, arthropods (spiders and scorpions), and marine animals"</a>.)</p><p class="headingAnchor" id="H2246834213"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First aid</strong> – First aid measures for patients with bites by North American (NA) Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) include (see <a class="local">'First aid'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Move them away from the snake and keep them calm.</p><p class="bulletIndent2"><span class="glyph">•</span>For extremity bites, remove any jewelry or constricting clothing and immobilize the affected extremity in a functional position at the level of the heart; some experts prefer elevation of extremity bites to reduce tissue swelling and pain.</p><p class="bulletIndent2"><span class="glyph">•</span>Rapidly transport to definitive care.</p><p class="bulletIndent2"><span class="glyph">•</span>Do <strong>not</strong> apply pressure immobilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial stabilization</strong> – In addition to antivenom, patients with a NA Crotalinae snakebite, may require (see <a class="local">'Initial stabilization'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Emergency endotracheal intubation and mechanical ventilation for patients with: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Bites to the face or neck </p><p class="bulletIndent3"><span class="glyph">-</span>Myokymia (rippling muscle movement of the face and extremities) with airway compromise </p><p class="bulletIndent3"><span class="glyph">-</span>Weakness and respiratory failure </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of shock including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fluid resuscitation with isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or balanced crystalloid solutions </p><p class="bulletIndent3"><span class="glyph">-</span>Blood as needed to maintain an acceptable hematocrit </p><p class="bulletIndent3"><span class="glyph">-</span>For fluid-refractory shock, vasoactive medications as for septic shock (see  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antivenom (marked local or systemic envenomation)</strong> – The decision to administer antivenom is based upon clinical findings  (<a class="graphic graphic_algorithm graphicRef138360" href="/z/d/graphic/138360.html" rel="external">algorithm 1</a>). Consultation with a medical toxicologist or other physician with expertise managing NA Crotalinae snakebites is encouraged <strong>before</strong> giving antivenom and to guide decisions about redosing of antivenom, prevention of early recurrent toxicity, and treatment of late hemotoxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – For patients with NA Crotalinae bites with <strong>any</strong> of the following, we recommend antivenom therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Initial treatment'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Progressive swelling</p><p class="bulletIndent3"><span class="glyph">-</span>Signs of hemotoxicity or other systemic toxicity  (<a class="graphic graphic_table graphicRef122086" href="/z/d/graphic/122086.html" rel="external">table 5</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Potential for airway obstruction (bites to the face or neck with any swelling) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial dosing</strong> – The recommended antivenom dosing is provided in the table  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>). Crotalidae Immune F(a<sub>b</sub>')<sub>2</sub> (equine), brand name Anavip (Fab2AV), and Crotalidae Polyvalent-immune Fab (ovine), brand name CroFab (FabAV), have similar efficacy for initial control of typical toxic effects; FabAV is associated with a higher risk for late hemotoxicity. For patients exhibiting neurotoxicity (muscle fasciculation and/or motor weakness), FabAV has been used with varying success; the efficacy of Fab2AV in patients with neurotoxicity is unknown. (See <a class="local">'Initial treatment'</a> above and <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of acute reactions</strong> – Antivenom administration should occur in a continuously monitored emergency or intensive care unit setting because it can cause anaphylaxis that requires emergency treatment as described in the rapid overviews for anaphylaxis in adults  (<a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">table 2</a>) and children  (<a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">table 3</a>). (See <a class="local">'Treatment of acute antivenom reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Redosing</strong> – The need for repeat antivenom doses depends on the response to initial therapy and the agent used  (<a class="graphic graphic_table graphicRef122011" href="/z/d/graphic/122011.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Inadequate response to initial dose – Regardless of the agent used, patients who do not achieve control of envenomation after the initial dose (eg, ongoing hemodynamic instability, persistent signs of systemic toxicity, progressive swelling, persistent hematologic toxicity) generally warrant repeat dosing under the guidance of a medical toxicologist. (See <a class="local">'Assessment of response and need for redosing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>FabAV (CroFab) maintenance dosing – For most patients receiving FabAV, we suggest regularly scheduled maintenance doses (two vials every six hours for three doses) rather than as-needed dosing alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prevention of early recurrent toxicity'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fab2AV (Anavip) as-needed dosing – Scheduled maintenance dosing is <strong>not</strong> necessary for patients receiving Fab2AV; however, they should be observed for 18 hours after receiving antivenom and additional doses may be required if local or hematologic effects re-emerge. (See <a class="local">'Assessment of response and need for redosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rhabdomyolysis</strong> – Rhabdomyolysis and elevated tissue pressures are additional complications of severe NA Crotalinae envenomation. Primary treatment of rhabdomyolysis consists of fluid repletion and evaluation for significant electrolyte abnormalities such as hyperkalemia, hyperphosphatemia, and/or hypocalcemia. (See  <a class="medical medical_review" href="/z/d/html/14034.html" rel="external">"Clinical features and diagnosis of heme pigment-induced acute kidney injury", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Compartment syndrome</strong> – Envenomation may rarely increase tissue pressures in the subcutaneous space and cause significant swelling, pain, and paresthesias. Patients with these findings should undergo removal of any dressing, constriction band, splint, cast, or restrictive clothing and elevation of the extremity. Antivenom administration is sufficient treatment in most patients; compartment syndrome requiring fasciotomy is rare. (See <a class="local">'Elevated tissue pressures'</a> above and <a class="local">'Compartment syndrome'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor envenomation (nonprogressive, local swelling and no systemic toxicity) </strong>– Initial management of patients with minor envenomation (swelling and skin changes adjacent to the bite site only without progressive swelling) and no bite to the face or neck consists of pain control, local wound care, elevating and immobilizing the affected limb, and tetanus immunization as needed. These patients do <strong>not</strong> require antivenom unless they develop marked or progressive swelling or systemic toxicity on repeated laboratory studies during 24 hours of observation. (See <a class="local">'Minor envenomation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential dry bite</strong> – Management of patients with a potential dry bite also consists of local wound care and tetanus prophylaxis, as needed. The need for hospitalization and duration of observation depends on the patient's risk of complications if they develop late progression of envenomation (see <a class="local">'Potential dry bite'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High risk – Hospital admission and observation for 24 hours with repeat laboratory studies every 8 hours is warranted for patients with any of the following risk factors for complications: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with bites to the face, neck, or lower extremity </p><p class="bulletIndent3"><span class="glyph">-</span>Children &lt;10 years old </p><p class="bulletIndent3"><span class="glyph">-</span>Adults &gt;65 years old</p><p class="bulletIndent3"><span class="glyph">-</span>Patients with medical comorbidities or poor social supports </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Not at high risk – All other patients warrant observation for 8 to 12 hours.</p><p></p><p class="bulletIndent2"><strong>ACKNOWLEDGMENT</strong> — We are saddened by the death of Steven A Seifert, MD, FAACT, FACMT, who passed away in May 2022. UpToDate gratefully acknowledges Dr. Seifert's outstanding work as an author for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Seifert S, White J, Currie BJ. Pressure bandaging for North American snake bite? No! Clin Toxicol (Phila) 2011; 49:883.</a></li><li><a class="nounderline abstract_t">Sheikh S, Leffers P. Emergency department management of North American snake envenomations. Emerg Med Pract 2018; 20:1.</a></li><li><a class="nounderline abstract_t">McKinney PE. Out-of-hospital and interhospital management of crotaline snakebite. Ann Emerg Med 2001; 37:168.</a></li><li><a class="nounderline abstract_t">Markenson D, Ferguson JD, Chameides L, et al. Part 13: First aid: 2010 American Heart Association and American Red Cross International Consensus on First Aid Science With Treatment Recommendations. Circulation 2010; 122:S582.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2.</a></li><li><a class="nounderline abstract_t">American College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, et al. Pressure immobilization after North American Crotalinae snake envenomation. Clin Toxicol (Phila) 2011; 49:881.</a></li><li><a class="nounderline abstract_t">Corbett SW, Anderson B, Nelson B, et al. Most lay people can correctly identify indigenous venomous snakes. Am J Emerg Med 2005; 23:759.</a></li><li><a class="nounderline abstract_t">Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347.</a></li><li><a class="nounderline abstract_t">Hall EL. Role of surgical intervention in the management of crotaline snake envenomation. Ann Emerg Med 2001; 37:175.</a></li><li><a class="nounderline abstract_t">Stewart ME, Greenland S, Hoffman JR. First-aid treatment of poisonous snakebite: are currently recommended procedures justified? Ann Emerg Med 1981; 10:331.</a></li><li><a class="nounderline abstract_t">Alberts MB, Shalit M, LoGalbo F. Suction for venomous snakebite: a study of "mock venom" extraction in a human model. Ann Emerg Med 2004; 43:181.</a></li><li><a class="nounderline abstract_t">Vohra R, Cantrell FL, Williams SR. Fasciculations after rattlesnake envenomations: a retrospective statewide poison control system study. Clin Toxicol (Phila) 2008; 46:117.</a></li><li><a class="nounderline abstract_t">Farstad D, Thomas T, Chow T, et al. Mojave rattlesnake envenomation in southern California: a review of suspected cases. Wilderness Environ Med 1997; 8:89.</a></li><li><a class="nounderline abstract_t">Bush SP, Siedenburg E. Neurotoxicity associated with suspected southern Pacific rattlesnake (Crotalus viridis helleri) envenomation. Wilderness Environ Med 1999; 10:247.</a></li><li><a class="nounderline abstract_t">Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann Emerg Med 2008; 51:407.</a></li><li><a class="nounderline abstract_t">Goto CS, Feng SY. Crotalidae polyvalent immune Fab for the treatment of pediatric crotaline envenomation. Pediatr Emerg Care 2009; 25:273.</a></li><li><a class="nounderline abstract_t">Yip L. Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite. Ann Emerg Med 2002; 39:648.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Kokko J, Schaeffer TH, et al. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med 2011; 57:128.</a></li><li><a class="nounderline abstract_t">Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030.</a></li><li><a class="nounderline abstract_t">Johnson PN, McGoodwin L, Banner W Jr. Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children. Emerg Med J 2008; 25:793.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Schaeffer TH, Kokko J, et al. Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review. BMC Emerg Med 2009; 9:13.</a></li><li><a class="nounderline abstract_t">Ruha AM, Curry SC, Beuhler M, et al. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med 2002; 39:609.</a></li><li><a class="nounderline abstract_t">Pizon AF, Riley BD, LoVecchio F, Gill R. Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations. Acad Emerg Med 2007; 14:373.</a></li><li class="breakAll">Protherics. CroFab: Crotalidae polyvalent immune Fab (ovine) product information. In: Nashville TN; 2000. https://www.fda.gov/media/74683/download (accessed August 2, 2019).</li><li><a class="nounderline abstract_t">Bush SP, Ruha AM, Seifert SA, et al. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila) 2015; 53:37.</a></li><li class="breakAll">Prescribing information. ANAVIP crotalidae immune F(ab’)2 (equine). https://www.fda.gov/media/92139/download (Accessed on April 19, 2021).</li><li><a class="nounderline abstract_t">Clark RF, Williams SR, Nordt SP, Boyer-Hassen LV. Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom. Ann Emerg Med 1997; 30:54.</a></li><li><a class="nounderline abstract_t">Richardson WH, Goto CS, Gutglass DJ, et al. Rattlesnake envenomation with neurotoxicity refractory to treatment with crotaline Fab antivenom. Clin Toxicol (Phila) 2007; 45:472.</a></li><li><a class="nounderline abstract_t">Ruha AM, Padilla-Jones A, Canning J, et al. Early Experience with Crotalidae Immune F(ab')2 Antivenom to Treat Arizona Rattlesnake Envenomations. J Med Toxicol 2022; 18:38.</a></li><li><a class="nounderline abstract_t">Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. Clin Toxicol (Phila) 2013; 51:3.</a></li><li><a class="nounderline abstract_t">Ghosh N, Henderson JA, Kim HG, Ancar FM. Rattlesnake Envenomation in the Third Trimester of Pregnancy. Obstet Gynecol 2018; 132:682.</a></li><li><a class="nounderline abstract_t">LaMonica GE, Seifert SA, Rayburn WF. Rattlesnake bites in pregnant women. J Reprod Med 2010; 55:520.</a></li><li><a class="nounderline abstract_t">Yano J, Zerden M, German B. Presumed Copperhead Snakebite and Antivenom Administration in the Third Trimester. Wilderness Environ Med 2019; 30:446.</a></li><li><a class="nounderline abstract_t">Corbett B, Clark RF. North American Snake Envenomation. Emerg Med Clin North Am 2017; 35:339.</a></li><li><a class="nounderline abstract_t">Spyres MB, Skolnik AB, Moore EC, et al. Comparison of Antivenom Dosing Strategies for Rattlesnake Envenomation. Crit Care Med 2018; 46:e540.</a></li><li><a class="nounderline abstract_t">Ruha AM, Curry SC, Albrecht C, et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon 2011; 57:53.</a></li><li><a class="nounderline abstract_t">Mascarenas DN, Fullerton L, Smolinske SC, et al. Comparison of F(ab')2 and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab')2 in New Mexico. Toxicon 2020; 186:42.</a></li><li><a class="nounderline abstract_t">Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001; 37:196.</a></li><li><a class="nounderline abstract_t">Seifert SA, I Kirschner R, Martin N. Recurrent, persistent, or late, new-onset hematologic abnormalities in Crotaline snakebite. Clin Toxicol (Phila) 2011; 49:324.</a></li><li><a class="nounderline abstract_t">Seifert SA, Cano DN. Late, new-onset thrombocytopenia following rattlesnake envenomation without early thrombocytopenia or post-antivenom platelet increase. Clin Toxicol (Phila) 2020; 58:424.</a></li><li><a class="nounderline abstract_t">Levine M, Ruha AM, Padilla-Jones A, et al. Bleeding following rattlesnake envenomation in patients with preenvenomation use of antiplatelet or anticoagulant medications. Acad Emerg Med 2014; 21:301.</a></li><li><a class="nounderline abstract_t">Moore EC, Porter LM, Ruha AM. Rattlesnake venom-induced recurrent coagulopathy in first trimester pregnant women - Two Cases. Toxicon 2019; 163:8.</a></li><li><a class="nounderline abstract_t">Kitchens C, Eskin T. Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol 2008; 4:180.</a></li><li><a class="nounderline abstract_t">Williams KL, Woslager M, Garland SL, et al. Use of polyvalent equine anti-viper serum to treat delayed coagulopathy due to suspected Sistrurus miliarius streckeri envenomation in two children. Clin Toxicol (Phila) 2017; 55:326.</a></li><li><a class="nounderline abstract_t">Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 2001; 37:189.</a></li><li><a class="nounderline abstract_t">Boyer LV, Chase PB, Degan JA, et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms. Toxicon 2013; 74:101.</a></li><li><a class="nounderline abstract_t">Yin S, Kokko J, Lavonas E, et al. Factors associated with difficulty achieving initial control with crotalidae polyvalent immune fab antivenom in snakebite patients. Acad Emerg Med 2011; 18:46.</a></li><li><a class="nounderline abstract_t">Brandehoff N, Dalton A, Daugherty C, et al. Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019-2021. J Med Toxicol 2023; 19:248.</a></li><li><a class="nounderline abstract_t">Gold BS, Barish RA, Rudman MS. Refractory thrombocytopenia despite treatment for rattlesnake envenomation. N Engl J Med 2004; 350:1912.</a></li><li><a class="nounderline abstract_t">Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181.</a></li><li><a class="nounderline abstract_t">Hutchinson, RH. On the incidence of snakebite poisoning in the United States and the results of newer methods of treatment. Bull Antivenom Institute of America 1929; III:43.</a></li><li><a class="nounderline abstract_t">do Amaral A. The anti-snakebite campaign in Texas and in the subtropical United States. Bull Antivenom Institute of America 1927; I:77.</a></li><li><a class="nounderline abstract_t">Seifert SA, Boyer LV, Benson BE, Rogers JJ. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. Clin Toxicol (Phila) 2009; 47:327.</a></li><li><a class="nounderline abstract_t">Ruha AM, Kleinschmidt KC, Greene S, et al. The Epidemiology, Clinical Course, and Management of Snakebites in the North American Snakebite Registry. J Med Toxicol 2017; 13:309.</a></li><li><a class="nounderline abstract_t">Burch JM, Agarwal R, Mattox KL, et al. The treatment of crotalid envenomation without antivenin. J Trauma 1988; 28:35.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Gerardo CJ. Letter to the editor: "Safety of nonsteroidal anti-inflammatory drugs in copperhead snakebite patients" by Pham and Mullins, Clin Toxicol 2018 May 18. Clin Toxicol (Phila) 2019; 57:144.</a></li><li><a class="nounderline abstract_t">Pham HX, Mullins ME. Safety of nonsteroidal anti-inflammatory drugs in copperhead snakebite patients. Clin Toxicol (Phila) 2018; 56:1121.</a></li><li><a class="nounderline abstract_t">Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev 2015; 29:82.</a></li><li><a class="nounderline abstract_t">White J. Snake venoms and coagulopathy. Toxicon 2005; 45:951.</a></li><li class="breakAll">Walter FG, Chase PB, Fernandez MC, McNally J. Venomous snakes. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, Philadelphia 2007. p.399.</li><li><a class="nounderline abstract_t">Tanen DA, Danish DC, Grice GA, et al. Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation. Ann Emerg Med 2004; 44:99.</a></li><li><a class="nounderline abstract_t">Shaw BA, Hosalkar HS. Rattlesnake bites in children: antivenin treatment and surgical indications. J Bone Joint Surg Am 2002; 84-A:1624.</a></li><li><a class="nounderline abstract_t">Hardy DL Sr, Zamudio KR. Compartment syndrome, fasciotomy, and neuropathy after a rattlesnake envenomation: aspects of monitoring and diagnosis. Wilderness Environ Med 2006; 17:36.</a></li><li><a class="nounderline abstract_t">Gold BS, Barish RA, Dart RC, et al. Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures. J Emerg Med 2003; 24:285.</a></li><li><a class="nounderline abstract_t">Heise CW, Ruha AM, Padilla-Jones A, et al. Clinical predictors of tissue necrosis following rattlesnake envenomation. Clin Toxicol (Phila) 2018; 56:281.</a></li><li><a class="nounderline abstract_t">August JA, Boesen KJ, Hurst NB, et al. Prophylactic Antibiotics Are Not Needed Following Rattlesnake Bites. Am J Med 2018; 131:1367.</a></li><li><a class="nounderline abstract_t">Gerardo CJ, Quackenbush E, Lewis B, et al. The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med 2017; 70:233.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med 2004; 43:200.</a></li><li><a class="nounderline abstract_t">Whitley RE. Conservative treatment of copperhead snakebites without antivenin. J Trauma 1996; 41:219.</a></li><li><a class="nounderline abstract_t">Caravati EM. Copperhead bites and Crotalidae polyvalent immune Fab (ovine): routine use requires evidence of improved outcomes. Ann Emerg Med 2004; 43:207.</a></li><li><a class="nounderline abstract_t">Walker JP, Morrison RL. Current management of copperhead snakebite. J Am Coll Surg 2011; 212:470.</a></li><li><a class="nounderline abstract_t">Greene SC, Folt J, Wyatt K, Brandehoff NP. Epidemiology of fatal snakebites in the United States 1989-2018. Am J Emerg Med 2021; 45:309.</a></li></ol></div><div id="topicVersionRevision">Topic 121865 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067012" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pressure bandaging for North American snake bite? No!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130010" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Emergency department management of North American snake envenomations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174235" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Out-of-hospital and interhospital management of crotaline snakebite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956261" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Part 13: First aid: 2010 American Heart Association and American Red Cross International Consensus on First Aid Science With Treatment Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21291549" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067011" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pressure immobilization after North American Crotalinae snake envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182984" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Most lay people can correctly identify indigenous venomous snakes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151473" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bites of venomous snakes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174236" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Role of surgical intervention in the management of crotaline snake envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7015932" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : First-aid treatment of poisonous snakebite: are currently recommended procedures justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747805" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Suction for venomous snakebite: a study of "mock venom" extraction in a human model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18259958" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fasciculations after rattlesnake envenomations: a retrospective statewide poison control system study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990148" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mojave rattlesnake envenomation in southern California: a review of suspected cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10628285" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neurotoxicity associated with suspected southern Pacific rattlesnake (Crotalus viridis helleri) envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191286" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369845" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Crotalidae polyvalent immune Fab for the treatment of pediatric crotaline envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023708" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952098" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525706" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033492" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545426" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023703" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296804" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361165" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361165" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209226" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503249" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rattlesnake envenomation with neurotoxicity refractory to treatment with crotaline Fab antivenom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34665424" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early Experience with Crotalidae Immune F(ab')2 Antivenom to Treat Arizona Rattlesnake Envenomations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23298218" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of envenomations during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30095759" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rattlesnake Envenomation in the Third Trimester of Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21291042" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rattlesnake bites in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699647" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Presumed Copperhead Snakebite and Antivenom Administration in the Third Trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411931" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : North American Snake Envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29521714" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of Antivenom Dosing Strategies for Rattlesnake Envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920516" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763251" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of F(ab')2 and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab')2 in New Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174239" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563909" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recurrent, persistent, or late, new-onset hematologic abnormalities in Crotaline snakebite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31387414" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Late, new-onset thrombocytopenia following rattlesnake envenomation without early thrombocytopenia or post-antivenom platelet increase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628755" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bleeding following rattlesnake envenomation in patients with preenvenomation use of antiplatelet or anticoagulant medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880187" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rattlesnake venom-induced recurrent coagulopathy in first trimester pregnant women - Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821492" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28165801" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of polyvalent equine anti-viper serum to treat delayed coagulopathy due to suspected Sistrurus miliarius streckeri envenomation in two children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174238" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23948058" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21166732" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Factors associated with difficulty achieving initial control with crotalidae polyvalent immune fab antivenom in snakebite patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37115482" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115843" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Refractory thrombocytopenia despite treatment for rattlesnake envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174237" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy, safety, and use of snake antivenoms in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : On the incidence of snakebite poisoning in the United States and the results of newer methods of treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The anti-snakebite campaign in Texas and in the subtropical United States</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19514880" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28975491" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Epidemiology, Clinical Course, and Management of Snakebites in the North American Snakebite Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3339661" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The treatment of crotalid envenomation without antivenin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306814" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Letter to the editor: "Safety of nonsteroidal anti-inflammatory drugs in copperhead snakebite patients" by Pham and Mullins, Clin Toxicol 2018 May 18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774760" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety of nonsteroidal anti-inflammatory drugs in copperhead snakebite patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25556574" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hematologic effects and complications of snake envenoming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922768" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Snake venoms and coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922768" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Snake venoms and coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15278079" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208920" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rattlesnake bites in children: antivenin treatment and surgical indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538944" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Compartment syndrome, fasciotomy, and neuropathy after a rattlesnake envenomation: aspects of monitoring and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12676299" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885114" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical predictors of tissue necrosis following rattlesnake envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392637" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prophylactic Antibiotics Are Not Needed Following Rattlesnake Bites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601268" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747809" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8760527" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Conservative treatment of copperhead snakebites without antivenin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747810" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Copperhead bites and Crotalidae polyvalent immune Fab (ovine): routine use requires evidence of improved outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21463771" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Current management of copperhead snakebite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046301" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Epidemiology of fatal snakebites in the United States 1989-2018.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
